Dr. Reddy’s Laboratories Ltd (NYSE:RDY) announced today that it has acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy. The deal has been completed via Dr Reddy’s Italian subsidiary, Reddy Pharma Italia SpA, which has been engaged in building a pipeline of registrations since its incorporation. The acquisition provides access to an essential product portfolio, a pipeline of registration applications, and a sales and marketing organisation. Financial terms and conditions of the transaction are not being disclosed.

Commenting on the acquisition, Mr VS Vasudevan, President & Head – Europe Operations said, “Dr Reddy’s has taken a significant step forward by establishing its business in the third largest pharmaceutical market in Europe. The acquisition has been well timed, since Dr Reddy’s will be able to immediately supplement the Jet Generici portfolio via its own pipeline. We already have registration for one significant Dr Reddy’s product, and a strong pipeline of registration applications. We believe that this strategic investment will generate substantial opportunities for long-term value creation in one of the fastest growing generic markets of the world.”

Sourced from: Dr. Reddy’s Laboratories Ltd

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Buy Dr Reddy’s Labs: Indiabulls Securities
• Dr Reddy’s surges 5% on GSK partnership
• Dr Reddy’s FY08 revenue at Rs 50006mn; EBITDA at Rs 9736mn
• Marksans Pharma acquires Relonchem Ltd
• Technical view:: Ashok Leyland, Dr.Reddy’s & Exide Industries